Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 730 | 158 | 560 |
| Samples | 646 | 140 | 497 |
| Peptides | 514 | 95 | 434 |
Function
INO80 · INO80 complex ATPase subunit
This gene encodes a subunit of the chromatin remodeling complex, which is classified into subfamilies depending on sequence features apart from the conserved ATPase domain. This protein is the catalytic ATPase subunit of the INO80 chromatin remodeling complex, which is characterized by a DNA-binding domain. This protein is proposed to bind DNA and be recruited by the YY1 transcription factor to activate certain genes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000648947 | Q9ULG1 | 730 | 514 |
Gene Properties
Recurrent Mutations
All 514 amino-acid changes on canonical ENST00000648947 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in INO80 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in INO80 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 12/40 30% | 0/0 0% |
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| Endometrial Carcinoma | 12/42 29% | 26/612 4% |
| Acute Myeloid Leukemia | 5/90 6% | 0/0 0% |
| Melanoma | 10/210 5% | 74/1899 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Bladder Carcinoma | 5/58 9% | 32/956 3% |
| Cervical Carcinoma | 2/35 6% | 13/422 3% |
| Colorectal Carcinoma | 14/143 10% | 65/3239 2% |
| Gastric Carcinoma | 3/74 4% | 38/1809 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 22/1390 2% |
| Burkitts Lymphoma | 3/32 9% | 1/196 1% |
| Other Solid Cancers | 1/94 1% | 26/1515 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 10/810 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Esophageal Squamous Cell Carcinoma | 5/51 10% | 24/2550 1% |
| Neuroendocrine Tumour | 6/154 4% | 2/577 0% |
| Head and Neck Carcinoma | 2/85 2% | 16/1574 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Ovarian Carcinoma | 3/109 3% | 8/998 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 14/1592 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Breast Carcinoma | 11/144 8% | 21/3264 1% |
| Glioma | 4/52 8% | 16/2127 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Hepatocellular Carcinoma | 0/46 0% | 19/2210 1% |
| Pancreatic Carcinoma | 3/89 3% | 11/1611 1% |
Mutation Distribution
Where INO80 is mutated · all tissues, split by cell line vs tissue
How many mutations in INO80 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 730 mutations in INO80
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|